January 26, 2009 - Theravance, Inc. announced today that it submitted a New Drug Application (NDA) to the U.S. FDA for telavancin, a novel, bactericidal, once-daily injectable investigational antibiotic, for the proposed indication to treat nosocomial pneumonia caused by Gram-positive bacteria such as methicillin-resistant Staphylococcus aureus
The details can be read here.
No comments:
Post a Comment